Science Pool

Evotec's partner Exscientia receives first CTA approval for Phase I/II trial of EXS-21546

Evotec’s partner Exscientia plc today announced clinical trial application (“CTA”) approval of a Phase I/II trial of EXS-21546, an A2a receptor antagonist, co-invented and developed through a collaboration between Exscientia and Evotec.

Read More

Twitter
LinkedIn
Email
Generated by Feedzy